相关实验视频

Updated: Jan 9, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

带有抗神经素186抗体的自身免疫性节节病

Ashik Anilkumar¹, Parameswaran Krishnan²

¹Neurology, Indo American Hospital Brain and spine Center, Vaikom, IND.

|December 8, 2025

概括

自身免疫性神经病变,特别是抗神经素186结节病变,需要早期抗体测试才能有效治疗. 及时诊断和向治疗,如rituximab提供显著的症状缓解.

科学领域:

神经学神经学
免疫学免疫学免疫学
临床案例研究临床案例研究

背景情况:

自身免疫性神经病变是一种免疫介导的神经病变的子类,其特点是特定的抗体配置文件.
早期发现自身免疫性神经病变对于症状管理和改善患者治疗结果至关重要.

研究的目的:

介绍一种抗神经素186结节病的病例,详细说明其临床表现.
讨论与这种罕见疾病相关的诊断和治疗挑战.

主要方法:

一个46岁的妇女的病例报告,在两年内,她的下肢疲软和外围疼痛逐渐增加.
对静脉注射免疫球蛋白和皮质类固醇的治疗反应的审查.
评估对利图西马布治疗的反应.

主要成果:

患者最初没有表现出标准治疗 (静脉注射免疫球蛋白,类固醇) 的改善.
在开始修复药治疗后,观察到显著的神经改善.
这一案例凸显了在自身免疫性神经病变中识别特定抗体的重要性.

结论:

早期抗体测试对于指导自身免疫结节病的有效管理策略至关重要.
利图西马布在患有抗神经素186结节病的患者中显示出有效性,该患者对其他治疗不耐药.
这一案例突显了自身免疫神经病变的异质性和需要量身定制的治疗方法.

关键词:

抗神经素186抗体的抗体自动抗体分析概况自身免疫性结节病的发生.免疫媒介的神经病变.免疫疗法免疫疗法利图西玛布治疗方法

更多相关视频

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis

Published on: September 26, 2012

相关概念视频

Autoimmune Disorders

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...